ClinicalTrials.gg
RecruitingNCT07413640MICRO-VARUpdated Oct 21, 2026

Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors

An observational study in Liver Neoplasm, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Central Hospital, Nancy, France · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 21, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
90
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 93 studies in Liver Neoplasms with a site in France — 16 open to participants now, 28 under way, 4 of them phase 3. Liver Neoplasms · France.

Planned enrollment
21st of 26
90 · median 303
Started
2026
with 2 others
Observational
26 of 93
11 open now
Primary completion
2026-07
later than 11 of 27 live
Registered
92nd of 93
by date

Among the 93 studies in Liver Neoplasms with a site in France, this one is the 21st largest by planned enrollment of the 26 observational ones that give a count, is one of 3 that started in 2026, is one of 26 observational ones, reaches primary completion later than 11 of the 27 other live ones, and was the 92nd registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

16 of the 93 studies in Liver Neoplasms with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Liver Neoplasms with a site in France, or all of them as a file.
02

Study summary

Microwave ablation is a minimally invasive technique whose planning relies on manufacturer tables derived from ex vivo models that do not account for patient or tumor-specific factors. In clinical practice, the actual ablation volume often differs from the planned volume due to liver characteristics, vascular proximity, and tumor biology.

This study aims to assess the variability between ablation small axis during percutaneous microwave ablation of liver lesions. The influence of patient-related (fibrosis, steatosis, portal flow) and tumor-related factors (location, histology, prior treatment) will be evaluated. Small axis and volume will be compared with volumes measured on immediate post-procedural CT and on CT/MRI at 6-12 weeks, accounting for expected tissue shrinkage.

03

Conditions studied

  • Liver Neoplasm

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients treated with percutaneous hepatic microwave ablation under CT or ultrasound guidance for one or more liver lesions with followed up imaging availables

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients
  • Treated with percutaneous hepatic microwave ablation under CT or ultrasound guidance
  • Adult treated for one or more liver lesions
  • Patients with available follow-up imaging

Exclusion criteria

Exclusion Criteria:

  • Two treatment cycles on the same lesion during the same session.
  • Reoperation on the same lesion.
  • Planned volume not available (no manufacturer data, not specified in the surgical report).
  • No control imaging injected between 1 and 4 months post-procedure.
  • Final ablation volume not measurable (e.g., artifacts, no injection on MRI).
  • No definitive diagnosis of the nature of the tumor on imaging and no histology available.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
90 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Small final ablation axis measured on the post-procedure imaging modality considered to be the most reliable.

    The final short axis will preferably be measured (in mm) on MRI at 6-12 weeks. If inter-patient variability in volume shrinkage exceeds 5%, the modality with the lowest relative variability (usually the immediate CT scan) will be used as the reference for estimating the final volume.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2026 to primary completion in Jul 2026, 5 months.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Dec 2026, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 17, 2026
StartActual
Feb 2, 2026
Primary completionActual
Jul 31, 2026
CompletionEst.
Dec 31, 2026was Jul 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 1, 2026→Jul 31, 2026 (actual)
Oct 21, 2026
Study completion
Jul 1, 2026→Dec 31, 2026
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Primary completion Jul 1, 2026→Jul 31, 2026 (now actual)
    Study completion Jul 1, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07413640
Responsible party
Valérie LAURENT (MD-PhD, Central Hospital, Nancy, France) — Principal investigator
First posted
Feb 17, 2026
Start date
Feb 2, 2026
Primary completion
Jul 31, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Oct 21, 2026

Study contacts

Valérie LAURENT, MD-PhD
Contact
v.laurent@chru-nancy.fr
33383157823
Astrée LEMORE, MD
Contact
a.lemore@chru-nancy.fr
33383157823

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion